October 27, 2021 11:47 AM EDT
Cell/Gene Tx
FDA+

Pfiz­er, No­var­tis, Janssen and oth­er biotechs sign on­to NIH/FDA pro­gram to de­vel­op new gene ther­a­pies for rare dis­eases

Zachary Brennan

Senior Editor

Ten top drug­mak­ers are join­ing forces with the NIH, the FDA and oth­er non­prof­its to stream­line the de­vel­op­ment of new gene ther­a­pies for those with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times